Davion Healthcare (DAVI) Registration filing summary

Company overview and business model

• Ireland-incorporated healthcare business developing and commercializing non-invasive home diagnostic tests for early detection, prevention and monitoring of health anomalies, including cancers.

• BreastCheck measures temperature differences across breast tissue, provides app-interpreted results in under 15 minutes and is positioned as an adjunct to—not a replacement for—mammography.

• Product development, design and manufacturing rely on universities, specialist firms and third parties; products are commercialized and distributed internationally through licensing agreements.

• Additional products include FootFlow for PAD and diabetes, Testic for testicular anomalies and ThermaDerm; further home tests are planned over the next few years.

Financial performance and metrics

• IFRS statements show zero revenue in FY2023 and FY2024; operating loss narrowed to €1.320m in FY2024 from €5.308m in FY2023.

• FY2024 R&D expense was €8,159 versus €3.016m in FY2023; administrative expense was €1.312m versus €2.293m.

• At Dec. 31, 2024, audited cash was €679, total assets €65.008m and equity €64.968m; current liabilities exceeded current assets by €31,607.

• Audited intangible assets remained at €65m cost; a third-party €260m fair-value assessment was not recognized in the financial statements because no active market existed.

• CEO support has funded operations; management cited a 12-month support letter and expected sufficient resources for at least 12 months, while anticipating losses and negative cash flow until late-2025 commercialization.

Use of proceeds and capital allocation

• Direct listing registers existing shares only; no proceeds will accrue from registration or resale, and any later financing would require a separate filing or exemption.

• Estimated registration and listing expenses total $871,900, including $295,000 Nasdaq listing fees and $250,000 each for legal and accounting fees.

• No cash dividends are planned for the foreseeable future; available funds and future earnings are intended to be retained for operations and business expansion.

• A separate registered offering or other financing may follow listing to support growth; management notes potential dilution from a future share issuance.